Objective To investigate the changes in serum thrombospondin-1 (TSP-1) and serum amyloid A1 (SAA1) levels in patients with coronary heart disease (CHD), and their predictive value for major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI).

Methods A total of 228 CHD patients treated with PCI were divided into the MACE group (68 cases) and non-MACE group (160 cases) according to the occurrence of MACE after PCI. Another 129 healthy physical examination subjects matching the general data of the observation group were selected as the control group. The Pearson method was used to analyze the correlation between serum TSP-1 and SAA1 expression levels, the multivariate Logistic regression was used to analyze the relevant factors affecting the occurrence of MACE in CHD patients after PCI, and the receiver operating characteristic (ROC) curve was used to analyze the predictive value of serum TSP-1 and SAA1 expression for MACE in patients with CHD after PCI.

Results The expression levels of serum TSP-1 and SAA1 in the observation group were higher than those in control group (P ＜ 0.05), and there was a significant positive correlation between the expression levels of serum TSP-1 and SAA1 (r = 0.737, P ＜ 0.05). The expression levels of serum TSP-1 and SAA1 in the MACE group were higher than those in the non-MACE group (P ＜ 0.05), and the age, TSP-1, and SAA1 were the risk factors of MACE in patients with coronary heart disease after PCI (P ＜ 0.05). The area under the curve (AUC) of TSP-1 and SAA1 in predicting MACE in CHD patients after PCI were 0.788 and 0.801, respectively, the AUC predicted by the combination of the two was 0.916, and the combined prediction was better than that of TSP-1 and SAA1 separately (Z_{combination-TSP-1} = 4.052, Z_{combination-SAA1} = 3.967, P ＜ 0.01).

Conclusions TSP-1 and SAA1 are both highly expressed in the serum of patients with CHD, and their combined detection has high predictive value for the occurrence of MACE in patients with CHD after PCI.